X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 58 filers reported holding X4 PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,718 | -94.8% | 1,576 | -90.8% | 0.00% | – |
| Q2 2023 | $33,236 | +553833.3% | 17,132 | +285433.3% | 0.00% | – |
| Q1 2023 | $6 | -100.0% | 6 | -99.9% | 0.00% | – |
| Q3 2022 | $17,000 | -86.0% | 10,000 | -81.1% | 0.00% | – |
| Q4 2021 | $121,000 | -85.0% | 53,031 | -65.3% | 0.00% | – |
| Q3 2021 | $808,000 | -41.5% | 152,831 | -28.1% | 0.00% | – |
| Q2 2021 | $1,382,000 | -24.5% | 212,620 | 0.0% | 0.00% | – |
| Q1 2021 | $1,831,000 | +33.9% | 212,620 | 0.0% | 0.00% | – |
| Q4 2020 | $1,367,000 | -9.0% | 212,620 | -4.2% | 0.00% | – |
| Q3 2020 | $1,502,000 | -76.9% | 221,912 | -68.2% | 0.00% | -100.0% |
| Q2 2020 | $6,503,000 | -6.8% | 697,800 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $6,978,000 | -27.5% | 697,800 | -22.5% | 0.00% | 0.0% |
| Q4 2019 | $9,630,000 | -15.8% | 900,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $11,439,000 | -15.3% | 900,000 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $13,500,000 | – | 900,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
| Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
| Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
| NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
| Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
| SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
| Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
| Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
| Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |